Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

gsk_boronia_australia

GSK triple combo COPD therapy shows superiority in Phase III trials

June 20, 2016 Research and Development, Sales and Marketing COPD, GSK, phase III

GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …
News

Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC

June 20, 2016 Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer

Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …
News
lab

Federal panel to review proposal for first human CRISPR test

June 20, 2016 Research and Development, Sales and Marketing crispr, gene editing, human testing, oncology

A US Federal safety board is set to review a proposal for the first human use of the gene editing …
News

Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer

June 17, 2016 Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …
News

Pfizer breaks ground on new $200 million biologics facility

June 17, 2016 Medical Communications, Research and Development Manufacturing Facility, Pfizer

Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …
News
6123892769_1befc31f38_o

WellBe bracelet, mobile app to help manage stress

June 17, 2016 Medical Communications, Research and Development HealthTech, WellBe, app, stress, wearable technology

Adding to the growing list of healthcare applications, a new technology claims to have created the first anti-stress biofeedback bracelet …
News
roche_close

Roche gets a NICE knockback for melanoma drug, Cotellic

June 16, 2016 Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche

The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …
News
chemo-web

SMC recommends treatment for potentially fatal chemotherapy-related disease

June 16, 2016 Research and Development, Sales and Marketing Menarini, SMC, adneuric

The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …
News
alzheimers_web_credit_shutterstock

Chiasma cuts staff by 33% after FDA rejects rare disease drug, Mycapssa

June 16, 2016 Research and Development, Sales and Marketing FDA, chiasma, cutbacks, failure, workforce cuts

US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …
News
flag_-_union_flag

UK biotech in great shape, according to new industry report

June 16, 2016 Research and Development Europe, UK, biotech, uk bioindustry association

The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …
News
roche

Roche secures EU approval for Gazyvaro in new lymphoma indication

June 16, 2016 Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma

Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …
News
teva_copy

Teva returns rights to heart cell therapy to Mesoblast

June 16, 2016 Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III

Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …
News
trials

Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA

June 15, 2016 Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals

Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
News
money_pills_2

Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals

June 15, 2016 Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure

Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
News
sobi

Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder

June 15, 2016 Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi

Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026